Highley MS - Search Results

1

Highley MS, Landuyt B, Prenen H, Harper PG, De Bruijn EA. Highley MS, et al. Pharmacol Rev. 2022 Jul;74(3):552-599. doi: 10.1124/pharmrev.120.000121. Pharmacol Rev. 2022. PMID: 35710137 Review.

2

Pharmacology of anticancer drugs in the elderly population.

Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT. Wildiers H, et al. Among authors: highley ms. Clin Pharmacokinet. 2003;42(14):1213-42. doi: 10.2165/00003088-200342140-00003. Clin Pharmacokinet. 2003. PMID: 14606930 Review.

3

Vascular endothelial growth factor and angiogenesis.

Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Hoeben A, et al. Among authors: highley ms. Pharmacol Rev. 2004 Dec;56(4):549-80. doi: 10.1124/pr.56.4.3. Pharmacol Rev. 2004. PMID: 15602010 Review.

4

Activated oxazaphosphorines are transported predominantly by erythrocytes.

Highley MS, Schrijvers D, Van Oosterom AT, Harper PG, Momerency G, Van Cauwenberghe K, Maes RA, De Bruijn EA, Edelstein MB. Highley MS, et al. Ann Oncol. 1997 Nov;8(11):1139-44. doi: 10.1023/a:1008261203803. Ann Oncol. 1997. PMID: 9426334 Free article.

5

Hyphenated techniques in anticancer drug monitoring. I. Capillary gas chromatography-mass spectrometry.

Guetens G, De Boeck G, Wood M, Maes RA, Eggermont AA, Highley MS, van Oosterom AT, de Bruijn EA, Tjaden UR. Guetens G, et al. Among authors: highley ms. J Chromatogr A. 2002 Nov 8;976(1-2):229-38. doi: 10.1016/s0021-9673(02)01228-1. J Chromatogr A. 2002. PMID: 12462614 Review.

6

Erythrocytes and the transfer of anticancer drugs and metabolites: a possible relationship with therapeutic outcome.

Dumez H, Highley M, Guetens G, De Boeck G, Hanauske A, van Oosterom AT, Maes RA, de Bruijn EA, Harper P. Dumez H, et al. Semin Oncol. 2001 Apr;28(2 Suppl 8):24-8. doi: 10.1016/s0093-7754(01)90209-x. Semin Oncol. 2001. PMID: 11395849

7

Everolimus alters imatinib blood partition in favour of the erythrocyte.

Prenen H, Guetens G, De Boeck G, Highley M, van Oosterom AT, de Bruijn EA. Prenen H, et al. J Pharm Pharmacol. 2006 Aug;58(8):1063-6. doi: 10.1211/jpp.58.8.0006. J Pharm Pharmacol. 2006. PMID: 16872552

8

Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.

Van Der Heyden SA, Highley MS, De Bruijn EA, Tjaden UR, Reeuwijk HJ, Van Slooten H, Van Oosterom AT, Maes RA. Van Der Heyden SA, et al. Among authors: highley ms. Br J Clin Pharmacol. 1999 Apr;47(4):351-6. doi: 10.1046/j.1365-2125.1999.00899.x. Br J Clin Pharmacol. 1999. PMID: 10233196 Free PMC article.

9

The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.

Dumez H, Guetens G, De Boeck G, Highley MS, Maes RA, van Oosterom AT, de Bruijn EA. Dumez H, et al. Among authors: highley ms. Clin Chem Lab Med. 2004;42(11):1219-27. doi: 10.1515/CCLM.2004.244. Clin Chem Lab Med. 2004. PMID: 15576286 Review.

10

Partitioning of ifosfamide and its metabolites between red blood cells and plasma.

Momerency G, Van Cauwenberghe K, Highley MS, Harper PG, Van Oosterom AT, De Bruijn EA. Momerency G, et al. Among authors: highley ms. J Pharm Sci. 1996 Mar;85(3):262-5. doi: 10.1021/js950156a. J Pharm Sci. 1996. PMID: 8699325

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page